Rachael Kent will speak on a panel discussing IP and arbitration.

Similar to banks, large IP owners have been slower than some to adopt international arbitration. Lately though, that appears to be changing. So, how can international arbitration be of help when in the intellectual property sphere? How can the international arbitration world meet the industry’s concerns about its usefulness, and what are the peculiarities of the IP disputes that may require creative thinking? And where will the arbitrators be found? 

The panelists will address: 

• Reasons IP firms have avoided arbitration, and how many of those are insurmountable
• IP owners who have had embraced international arbitration and why. Are there any themes? Is there a US-rest of the world divide?
• The most common types of IP-related arbitrations
• Particular issues in life sciences and molecule development
• Compulsory licensing disputes 
• Covid-19 related IP and life sciences disputes 
• Quantifying damages in patent infringement cases in pharma